HomeStock SectorsBioTechPriothera Secures €1.7 million...

Priothera Secures €1.7 million i-Nov Funding by Bpifrance for Rare Blood Cancer Clinical Program

Priothera Secures €1.7 million i-Nov Funding by Bpifrance for Rare Blood Cancer Clinical Program

Funding to support MOCART, a clinical programme evaluating mocravimod added to standard CAR-T cell therapy 

Saint-Louis, France and Dublin, Ireland – 24 June 2025 Priothera, a late-stage biopharma company pioneering the development of mocravimod, a novel oral sphingosine 1 phosphate (S1P) receptor modulator, to treat hematologic malignancies, today announced that it has been awarded nearly €1.7 million in non-dilutive funding through the i-Nov innovation competition. Part of the France 2030 initiative, i-Nov is a flagship French government program operated by Bpifrance to support breakthrough innovation from high-potential French companies across strategic sectors. The funding will support Priothera’s clinical programme to evaluate whether adding mocravimod to commercial CAR-T cell therapies could improve patient outcomes.

CAR-T cell therapies represent a novel and promising modality for the treatment of hematological malignancies. They have demonstrated the potential for remarkable clinical responses and durable disease control in patients with acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma and multiple myeloma. However, their use is still associated with significant challenges, as 40-60% of patients treated with CAR-T cells experience high-grade toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), a form of severe neurological toxicity.

Mocravimod is a novel, oral S1P receptor modulator with a unique dual mechanism of action that has the potential to enhance the effectiveness of CAR-T cell therapy by:

  • Reducing the incidence and severity of CRS and ICANS, and
  • Improving response rates and durability of treatment

We are honoured to receive this i-Nov funding from Bpifrance, which underscores the innovation and therapeutic potential of mocravimod beyond allo-HCT,” said Florent Gros, Co-Founder and CEO of Priothera. “With its unique immunomodulatory properties, mocravimod is well-positioned to become a key component in the next generation of cell therapy regimens. The MOCART trial represents an exciting expansion of our clinical development into CAR-T therapy, building on our deep expertise in allo-HCT and momentum from our ongoing global Phase 3 MO-TRANS trial in acute myeloid leukemia.”

Priothera continues to advance mocravimod in the MO-TRANS global Phase 3 study for patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (allo-HCT). The company remains focused on unlocking the full therapeutic potential of S1P receptor modulation across multiple settings in blood cancers.

***

About mocravimod
Mocravimod (KRP203) is a synthetic S1P receptor modulator being developed for the adjunctive and maintenance treatment of AML to enhance the curative potential of allo-HCT. Mocravimod’s dual mechanism of action preserves the graft-versus-leukemia (GvL) effect, critical for eliminating cancer cells while reducing the risk of graft-versus-host disease (GvHD), a major complication following allo-HCT. This novel treatment approach – mocravimod being the only S1P receptor modulator in development to treat blood cancers – tackles a high unmet medical need and aims to improve treatment outcomes and patients’ quality of life.

About Priothera
Priothera is a late-stage biopharma company pioneering the development of mocravimod, a potential new standard of care in hematologic cancers, in addition to cellular therapies such as hematopoietic cell transplantation and CAR-T cell therapies. Mocravimod is being developed as an adjunctive and maintenance therapy for hematological malignancies requiring allogeneic hematopoietic cell transplant (allo-HCT), focusing initially on acute myeloid leukemia (AML). Mocravimod is currently the only treatment with the potential to reduce transplant side effects of graft-versus-host disease (GvHD) without compromising the graft’s anticancer effect against leukemia (Graft-versus-Leukemia, or GvL), thereby enhancing the curative potential of allo-HCT.

Founded in 2020, Priothera operates in France, with headquarters in Dublin. The company is led by a highly experienced management team with deep expertise in hematology, oncology, immunology and cell-based therapies. Priothera is backed by leading international life sciences investors, including Fountain Healthcare Partners, abrdn, EarlyBird Venture Capital, BEI and Bpifrance Grand Est.

For more information please visit  www.priothera.com or follow Priothera on LinkedIn www.linkedin.com/company/priothera/

Contacts


Most Popular

More from Author

Read Now

Can Trump’s ‘Run It Hot’ Plan Trap the Fed and Jolt the Bond Market?

Trump wants to run the economy hot to out of debt. So, what are the implications for markets? The Trump administration’s plan for the next 12 months could look like the following: 1) More tariffs: threaten big tariffs by Aug 1st, and ‘’close deals’’ with higher tariff rates before...

Midyear Market Check: Bulls in Control, but Valuations and Sentiment Flash Caution

Don’t look now fans, but the first half of 2025 is in the books. As we embark on the second half of the year, I thought it would be a good idea to review the key areas of analysis for the stock market.Such a review includes my...

Weekly Market Outlook: Key Moves in Gold, EUR/USD, and USD/JPY

Global financial markets are entering a crucial week loaded with high-impact macroeconomic developments and policy events that could redefine short-term trends across currencies, commodities, and equities. Central banks once again take the spotlight, with both the Reserve Bank of Australia (RBA) and the Reserve Bank of New...

Trump’s New Tariffs Shake Markets as Yen and ETFs Slide – iShares MSCI Japan Index Fund (ARCA:EWJ), iShares MSCI Malaysia Index Fund (ARCA:EWM)

The U.S. dollar is notching its strongest one-day gain against the Japanese yen in nearly two months as traders react to President Donald Trump's sweeping new tariffs targeting multiple U.S. trading partners.Starting Aug. 1, all goods imported from Japan and other Asian trading partners will face a...

The Bull Market Is Alive and Well

The bull market is alive and well, even amid widespread talk of the “death of U.S. exceptionalism.” Early 2025 saw a sharp shift in investor sentiment. Concerns over erratic trade policy, soaring debt, and weakening pressure challenged America’s long-standing market dominance. Markets fell sharply in April...

Why Is Jasper Therapeutics Stock Falling On Monday? – Jasper Therapeutics (NASDAQ:JSPR)

Jasper Therapeutics, Inc. JSPR stock is experiencing a steep decline on Monday, plummeting by nearly 55%. This significant drop is accompanied by an exceptionally high trading volume of 9.9 million shares, vastly exceeding its average daily volume of 251.9K, according to data from Benzinga Pro.What Happened?The company...

Stocks Wobble as Trump Resurrects Tariff Threats Ahead of July 9 Deadline

Market participants were expecting an upbeat start to the week on the hope that trade deals might finally be announced as the Trump administration deadline of July 9 approaches. However, President Trump adopted a confrontational stance once more by announcing that the US will begin issuing tariff...

CAD/JPY Ready to Continue Rising Ahead of Employment Change and Unemployment Rate

For three months since April, the currency has shown strength against the . although at the moment the price still cannot break the small resistance area on the H4 timeframe. but it is expected that the fundamental impulses can move the market more significantlyFigure 1. CAD/JPY...

What’s Going On With Hims & Hers Health Stock On Monday? – Hims & Hers Health (NYSE:HIMS)

Hims & Hers Health, Inc. HIMS is currently experiencing a decline in its stock price, trading lower on Monday. The company’s stock has plummeted approximately 18% over the past month, reflecting recent challenges.A significant development contributing to this decline occurred in June 2025, when Novo Nordisk A/S...

Why Is Cogent Biosciences Stock Trading Higher On Monday? – Cogent Biosciences (NASDAQ:COGT)

Cogent Biosciences, Inc.‘s COGT bezuclastinib showed meaningful clinical benefit for patients with non-advanced systemic mastocytosis, a rare and debilitating immune disorder. With statistically significant improvements across all endpoints—including symptom reduction and biomarkers of mast cell activity—the data support the company's plan to file for Food and Drug Administration...

3 Bullish Setups to Watch in July Amid Seasonal Tailwinds

As the second half of the year begins, several bullish setups are emerging—each supported by seasonal patterns and historical data. is approaching multi-year highs following a strong June, while technical signals in the broader market and semiconductor sector point to continued momentum. Meanwhile, recent policy developments may...

The Energy Report: Listen to What OPEC Says

prices are shaking off a larger-than-expected OPEC production increase as the precious metals get hit by a ton of bricks after President Trump posted about new tariffs on BRIC Nations on his Truth Social account. Yet despite the talk about OPEC wanting to maintain its market share,...